Browse Drug Recalls
1,357 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,357 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,357 FDA drug recalls in IL.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Aug 31, 2026 | Zoladex (goserelin) implant, 3.6 mg, One single-Use Syringe packaged in a car... | Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor c... | Class II | TerSera Therapeutics LLC |
| Aug 20, 2026 | Reliable-1 Laboratories Lubricating Tears, Sterile, 0.5 FL OZ (15 mL) bottles... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | Walgreens Lubricant Eye Drops, Carboxymethylcellulose sodium 0.5%, Lubricant ... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | Major LubriFresh P.M. Nighttime Ointment, Net wt. 0.125 oz. (3.5 g) tubes, Di... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | Walgreens Lubricant Eye Drops, 0.5 FL OZ (15 mL) 1.0 FL OZ (30 mL) TOTAL, 2 c... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | Reliable -1 Laboratories, Sodium Chloride Hypertonicity Ophthalmic Solution, ... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | Lubricant Eye Drops-Cameron Pharmaceuticals, Carboxymethylcellulose Sodium 0.... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%, Lubricant Eye ... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%, Lubricant Eye ... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 20, 2026 | TRP The Relief Products* Gentle Eyes Lubricant Eye Drops, Carboxymethylcellul... | Lack of Assurance of Sterility | Class II | Sterling Pharmaceutical Services LLC |
| Aug 18, 2026 | 2% Chlorhexidine Gluconate* Cloth, Non-sterile, 6 Disposable cloths, Sage Pro... | Cross Contamination with Other Products | Class II | Sage Products, LLC |
| Aug 17, 2026 | Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corpo... | Presence of Particulate Matter: particulate matter identified as stainless steel particles in the... | Class I | Baxter Healthcare Corporation |
| Aug 17, 2026 | 0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 2... | Presence of particulate matter: Particulates identified as fiberglass | Class I | Baxter Healthcare Corporation |
| Aug 10, 2026 | Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx ... | Presence of particulate matter:An internal investigation at the firm found the product to contain... | Class I | Fresenius Kabi USA, LLC |
| Aug 6, 2026 | Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Vancomycin Injection, USP in 5% Dextrose, 1 g per 200mL (5 mg/mL), in GALAXY ... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY ... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 unit... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Vancomycin Injection, USP, in 0.9% Sodium Chloride, 1g per 200 mL (5 mg/mL) i... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Famotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Sin... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL ... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY ... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 400 mcg per ... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL (12 mg/mL) in GALA... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Nexterone (amiodarone HCI), 360 mg/200 mL (1.8 mg/mL) in GALAXY Single-Dose C... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 5... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Pantoprazole Sodium in 0.9% Sodium Chloride Injection, 80 mg/100 mL (0.8 mg/m... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL)... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 unit... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 6, 2026 | Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALA... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 4, 2026 | Morphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefille... | Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of ... | Class I | Fresenius Kabi USA, LLC |
| Jul 24, 2026 | Cefazolin in Dextrose, Injection, USP, 2g / 100mL (20mg / mL) Single-Dose Inf... | Presence of Particulate Matter | Class I | Baxter Healthcare Corporation |
| Jul 16, 2026 | Glycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill... | Presence of Particulate Matter: Hair was found in product | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL)... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Lidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single D... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL)... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 14, 2026 | Glycopyrrolate Oral Solution, 1 mg/5 mL, delivers 5 mL, Rx only, Pkg: Precisi... | Failed Impurities/Degradation Specifications | Class II | Precision Dose Inc. |
| May 18, 2026 | PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Ste... | Failed Stability Specifications | Class III | AbbVie Inc. |
| May 14, 2026 | Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius... | Failed Impurities/Degradations Specifications | Class III | Fresenius Kabi USA, LLC |
| May 4, 2026 | Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials,... | Failed Impurities/Degradation Specifications | Class III | Sagent Pharmaceuticals |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 mL... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL i... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 50 mL x60, Becton, Dickson and Company, ... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP 0.9% (450 mg per 50 mL) (9 mg per mL) 50 ... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 1,000 mL... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL f... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 m... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL f... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.